HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987

Don Des Jarlais, Samuel R. Friedman, David M. Novick, J. L. Sotheran, Pauline Thomas, Stanley R. Yancovitz, Donna Mildvan, John Weber, Mary Jeanne Kreek, Robert Maslansky, Sarah Bartelme, Thomas Spira, Michael Marmor

Research output: Contribution to journalArticle

Abstract

Intravenous drug users are the second largest group to develop the acquired immunodeficiency syndrome, and they are the primary source for heterosexual and perinatal transmission in the United States and Europe. Understanding long-term trends in the spread of human immunodeficiency virus among intravenous drug users is critical to controlling the acquired immunodeficiency syndrome epidemic. Acquired immunodeficiency syndrome surveillance data and seroprevalence studies of drug treatment program entrants are used to trace seroprevalence trends among intravenous drug users in the borough of Manhattan. The virus entered this drug-using group during the mid-1970s and spread rapidly in 1979 through 1983. From 1984 through 1987, the seroprevalence rate stabilized between 55% and 60%—well below hepatitis B seroprevalence rates. This relatively constant rate is attributed to new infections, new seronegative persons beginning drug injection, seropositive persons leaving drug injection, and increasing conscious risk reduction.

Original languageEnglish (US)
Pages (from-to)1008-1012
Number of pages5
JournalJAMA: The Journal of the American Medical Association
Volume261
Issue number7
DOIs
StatePublished - Feb 17 1989

Fingerprint

Seroepidemiologic Studies
Drug Users
HIV Infections
HIV-1
Acquired Immunodeficiency Syndrome
Pharmaceutical Preparations
Injections
Heterosexuality
Risk Reduction Behavior
Hepatitis B
HIV
Viruses
Infection
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987. / Des Jarlais, Don; Friedman, Samuel R.; Novick, David M.; Sotheran, J. L.; Thomas, Pauline; Yancovitz, Stanley R.; Mildvan, Donna; Weber, John; Kreek, Mary Jeanne; Maslansky, Robert; Bartelme, Sarah; Spira, Thomas; Marmor, Michael.

In: JAMA: The Journal of the American Medical Association, Vol. 261, No. 7, 17.02.1989, p. 1008-1012.

Research output: Contribution to journalArticle

Des Jarlais, D, Friedman, SR, Novick, DM, Sotheran, JL, Thomas, P, Yancovitz, SR, Mildvan, D, Weber, J, Kreek, MJ, Maslansky, R, Bartelme, S, Spira, T & Marmor, M 1989, 'HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987', JAMA: The Journal of the American Medical Association, vol. 261, no. 7, pp. 1008-1012. https://doi.org/10.1001/jama.1989.03420070058030
Des Jarlais, Don ; Friedman, Samuel R. ; Novick, David M. ; Sotheran, J. L. ; Thomas, Pauline ; Yancovitz, Stanley R. ; Mildvan, Donna ; Weber, John ; Kreek, Mary Jeanne ; Maslansky, Robert ; Bartelme, Sarah ; Spira, Thomas ; Marmor, Michael. / HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987. In: JAMA: The Journal of the American Medical Association. 1989 ; Vol. 261, No. 7. pp. 1008-1012.
@article{b240feb84c614563b901a73cf582cff8,
title = "HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987",
abstract = "Intravenous drug users are the second largest group to develop the acquired immunodeficiency syndrome, and they are the primary source for heterosexual and perinatal transmission in the United States and Europe. Understanding long-term trends in the spread of human immunodeficiency virus among intravenous drug users is critical to controlling the acquired immunodeficiency syndrome epidemic. Acquired immunodeficiency syndrome surveillance data and seroprevalence studies of drug treatment program entrants are used to trace seroprevalence trends among intravenous drug users in the borough of Manhattan. The virus entered this drug-using group during the mid-1970s and spread rapidly in 1979 through 1983. From 1984 through 1987, the seroprevalence rate stabilized between 55{\%} and 60{\%}—well below hepatitis B seroprevalence rates. This relatively constant rate is attributed to new infections, new seronegative persons beginning drug injection, seropositive persons leaving drug injection, and increasing conscious risk reduction.",
author = "{Des Jarlais}, Don and Friedman, {Samuel R.} and Novick, {David M.} and Sotheran, {J. L.} and Pauline Thomas and Yancovitz, {Stanley R.} and Donna Mildvan and John Weber and Kreek, {Mary Jeanne} and Robert Maslansky and Sarah Bartelme and Thomas Spira and Michael Marmor",
year = "1989",
month = "2",
day = "17",
doi = "10.1001/jama.1989.03420070058030",
language = "English (US)",
volume = "261",
pages = "1008--1012",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "7",

}

TY - JOUR

T1 - HIV-1 Infection Among Intravenous Drug Users in Manhattan, New York City, From 1977 Through 1987

AU - Des Jarlais, Don

AU - Friedman, Samuel R.

AU - Novick, David M.

AU - Sotheran, J. L.

AU - Thomas, Pauline

AU - Yancovitz, Stanley R.

AU - Mildvan, Donna

AU - Weber, John

AU - Kreek, Mary Jeanne

AU - Maslansky, Robert

AU - Bartelme, Sarah

AU - Spira, Thomas

AU - Marmor, Michael

PY - 1989/2/17

Y1 - 1989/2/17

N2 - Intravenous drug users are the second largest group to develop the acquired immunodeficiency syndrome, and they are the primary source for heterosexual and perinatal transmission in the United States and Europe. Understanding long-term trends in the spread of human immunodeficiency virus among intravenous drug users is critical to controlling the acquired immunodeficiency syndrome epidemic. Acquired immunodeficiency syndrome surveillance data and seroprevalence studies of drug treatment program entrants are used to trace seroprevalence trends among intravenous drug users in the borough of Manhattan. The virus entered this drug-using group during the mid-1970s and spread rapidly in 1979 through 1983. From 1984 through 1987, the seroprevalence rate stabilized between 55% and 60%—well below hepatitis B seroprevalence rates. This relatively constant rate is attributed to new infections, new seronegative persons beginning drug injection, seropositive persons leaving drug injection, and increasing conscious risk reduction.

AB - Intravenous drug users are the second largest group to develop the acquired immunodeficiency syndrome, and they are the primary source for heterosexual and perinatal transmission in the United States and Europe. Understanding long-term trends in the spread of human immunodeficiency virus among intravenous drug users is critical to controlling the acquired immunodeficiency syndrome epidemic. Acquired immunodeficiency syndrome surveillance data and seroprevalence studies of drug treatment program entrants are used to trace seroprevalence trends among intravenous drug users in the borough of Manhattan. The virus entered this drug-using group during the mid-1970s and spread rapidly in 1979 through 1983. From 1984 through 1987, the seroprevalence rate stabilized between 55% and 60%—well below hepatitis B seroprevalence rates. This relatively constant rate is attributed to new infections, new seronegative persons beginning drug injection, seropositive persons leaving drug injection, and increasing conscious risk reduction.

UR - http://www.scopus.com/inward/record.url?scp=0024581966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024581966&partnerID=8YFLogxK

U2 - 10.1001/jama.1989.03420070058030

DO - 10.1001/jama.1989.03420070058030

M3 - Article

C2 - 2915408

AN - SCOPUS:0024581966

VL - 261

SP - 1008

EP - 1012

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 7

ER -